+1 #(S1 (S (NP (NN _PROT1_)) (VP (VBZ stimulates) (NP (NN _PROT2_) (NN production)) (PP (IN in) (NP (JJ dose-dependent) (NN fashion))) (PP (IN as) (NP (NN well))))))
-1 #(S1 (S (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NN binding))) (PP (IN in) (NP (JJ human) (NN myometrium))))))
+1 #(S1 (S (NP (NP (NN Carbachol)) (CC and) (NP (NN _PROT1_))) (VP (VBP stimulate) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (JJ _PROT2_) (NNS _PROT2_))) (PP (IN in) (NP (NP (DT the) (NN guinea) (NN pig)) (NN myometrium)))))))
+1 #(S1 (S (PP (IN In) (NP (NP (DT the) (NP (NN guinea) (NN pig)) (NN myometrium)) (VP (VBN prelabelled) (PP (IN with) (NP (ADJP (NN myo-[2-3H) (-RRB- -RSB-) (JJ inositol))))))) (, ,) (NP (NP (NN carbachol)) (CC and) (NP (NN _PROT1_))) (VP (VBD enhanced) (NP (NP (DT a) (ADJP (ADJP (JJ concentration-dependent)) (CC and) (ADJP (JJ rapid))) (NN release)) (PP (IN of) (NP (NN _PROT2_))) (SBAR (WHNP (WDT which)) (S (VP (VBD preceded) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN IP2)) (CC and) (NP (NN IP1))))))))))))
-1 #(S1 (S (S (NP (PRP They)) (VP (VBP are) (VP (VBN needed) (PP (IN for) (NP (NP (DT the) (NN catabolism)) (PP (IN of) (NP (NP (NN _PROT1_)) (, ,) (NP (NN bile) (NNS acids)) (, ,) (CC and) (NP (NN steroid) (NNS hormones))))))))) (: ;) (S (NP (PRP they)) (VP (VB hydrolyze) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NN _PROT2_) (NNS glycosides))) (PP (TO to) (NP (NNS anticarcinogens)))))) (: ;) (CC and) (S (NP (PRP they)) (VP (VB detoxify) (NP (JJ certain) (NNS carcinogens))))))
-1 #(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (VBN isolated) (NN rat) (NNS diaphragms)) (CC and) (NP (NNS adipocytes)))) (PP (IN with) (NP (NN PIG-P))) (PP (CONJP (RB as) (RB well) (IN as)) (PP (IN with) (NP (NP (JJ other) (NNS agents)) (VP (VBG exerting) (NP (ADJP (RB partially) (JJ _PROT1_)) (NN activity))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ PI-specific) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PLC)) (-RRB- -RRB-))) (CC and) (NP (DT the) (NN sulfonylurea) (NN glimepiride)))))) (, ,))) (VP (VBD triggered) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (DT the) (JJ caveolar) (NN marker) (NN protein) (NN caveolin))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB apparently)) (VP (VBN correlated) (PP (IN with) (NP (NP (NN stimulation)) (PP (IN of) (NP (NN lipogenesis)))))))))))))
-1 #(S1 (S (ADVP (RB Strikingly)) (, ,) (PP (IN in) (NP (NP (NNS adipocytes)) (VP (VBN subjected) (PP (TO to) (NP (NP (JJ combined) (NN trypsin/salt) (NN treatment)) (, ,) (NP (NN PIG-P)) (, ,) (NP (JJ PI-specific) (NN _PROT1_)) (, ,) (CC and) (NP (NN glimepiride))))))) (VP (VBD failed) (S (ADVP (RB completely)) (VP (TO to) (VP (VB provoke) (NP (JJ _PROT2_) (NNS effects))))))))
+1 #(S1 (S (NP (NP (JJ Neural) (NN site)) (PP (IN of) (NP (NN _PROT1_) (NN influence))) (PP (IN on) (NP (NP (NP (NN neuropeptide) (NN Y)) (NN signaling) (NNS pathways)) (VP (VBG altering) (NP (NP (NN feeding)) (CC and) (NP (NN _PROT2_) (NN _PROT2_)))))))))
-1 #(S1 (S (S (NP (NP (NN NPY)) (PP (IN in) (NP (DT the) (NNS PVN)))) (VP (VP (VBZ increases) (NP (NN feeding))) (CC and) (VP (VBZ decreases) (NP (NP (NP (NN _PROT1_) (NN _PROT1_) (-LRB- -LRB-) (NN UCP) (-RRB- -RRB-)) (NN activity)) (PP (IN in) (NP (NN brown) (NN fat))))))) (, ,) (IN whereas) (S (NP (NN _PROT2_)) (VP (VBZ decreases) (NP (NP (NN NPY) (NN biosynthesis)) (PP (IN in) (NP (DT the) (NN Arc))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB presumably)) (VP (VBZ decreases) (NP (NN PVN) (NN NPY))))))))))
+1 #(S1 (S (ADVP (RB Next)) (, ,) (NP (PRP we)) (VP (VBD determined) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VP (VBZ decreases) (NP (NN NPY))) (CC and) (VP (VBZ increases) (NP (NN _PROT2_) (NN gene) (NN expression)))))))))
-1 #(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (JJ immunocytochemical) (NNS studies)) (VP (VBD showed) (NP (NP (DT the) (NN _PROT1_) (JJ _PROT1_) (JJ neuronal) (NN MAC) (NN expression)) (PP (IN on) (NP (DT the) (NN SH-SY5Y) (NNS cells)))) (SBAR (IN after) (S (NP (NN CD59)) (VP (VBD was) (VP (VP (VBN removed) (PP (IN by) (NP (NN _PROT2_)))) (CC or) (VP (VBN blocked) (PP (IN by) (NP (CD anti-CD59) (NN antibody)))))))))))
-1 #(S1 (S (NP (NP (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))) (NN gene) (NN expression)) (: :) (NP (NP (NP (NN modulation)) (PP (IN by) (NP (NN food) (NN restriction)))) (CC and) (NP (NN _PROT_))))))
-1 #(S1 (S (NP (NP (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))) (NN gene) (NN expression)) (: :) (NP (NP (NP (NN modulation)) (PP (IN by) (NP (NN food) (NN restriction)))) (CC and) (NP (NN _PROT_))))))
+1 #(S1 (S (NP (NP (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))) (NN gene) (NN expression)) (: :) (NP (NP (NP (NN modulation)) (PP (IN by) (NP (NN food) (NN restriction)))) (CC and) (NP (NN _PROT2_))))))
-1 #(S1 (S (NP (NP (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (NN gene) (NN expression)) (: :) (NP (NP (NP (NN modulation)) (PP (IN by) (NP (NN food) (NN restriction)))) (CC and) (NP (NN _PROT_))))))
+1 #(S1 (S (NP (NP (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_))) (NN gene) (NN expression)) (: :) (NP (NP (NP (NN modulation)) (PP (IN by) (NP (NN food) (NN restriction)))) (CC and) (NP (NN _PROT2_))))))
-1 #(S1 (S (NP (NP (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_))) (NN gene) (NN expression)) (: :) (NP (NP (NP (NN modulation)) (PP (IN by) (NP (NN food) (NN restriction)))) (CC and) (NP (NN _PROT2_))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (NN food) (NN restriction)) (CC and) (NP (NN _PROT1_) (NN administration))) (PP (IN on) (NP (NP (JJ several) (NNS transcripts)) (VP (VBN involved) (PP (IN in) (NP (NN energy) (NN homeostasis)))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (NP (NP (NP (NN _PROT2_)) (, ,) (NP (VBG _PROT_) (NNS _PROT_) (-LRB- -LRB-) (NN UCP) (-RRB- -RRB-) (CD 1) (, ,) (CD 2) (CC and) (CD 3)) (, ,) (NP (NP (NN lipoprotein) (NN lipase)) (PRN (-LRB- -LRB-) (NP (NN LPL)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ beta3-adrenergic) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN beta3AR)) (-RRB- -RRB-))) (CC and) (NP (JJ hormone-sensitive) (NN lipase))) (PRN (-LRB- -LRB-) (NP (NN HSL)) (-RRB- -RRB-))) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (JJ brown) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (CC and) (NP (JJ epididymal) (-LRB- -LRB-) (NN EWAT) (-RRB- -RRB-) (CC and) (JJ perirenal) (-LRB- -LRB-) (NN PWAT) (-RRB- -RRB-) (JJ white) (NN adipose) (NN tissue)))) (PP (IN in) (NP (NP (CD three) (NNS groups)) (PP (IN of) (NP (NNS rats))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (NN food) (NN restriction)) (CC and) (NP (NN _PROT1_) (NN administration))) (PP (IN on) (NP (NP (JJ several) (NNS transcripts)) (VP (VBN involved) (PP (IN in) (NP (NN energy) (NN homeostasis)))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (NP (NP (NP (NN _PROT_)) (, ,) (NP (VBG _PROT2_) (NNS _PROT2_) (-LRB- -LRB-) (NN UCP) (-RRB- -RRB-) (CD 1) (, ,) (CD 2) (CC and) (CD 3)) (, ,) (NP (NP (NN lipoprotein) (NN lipase)) (PRN (-LRB- -LRB-) (NP (NN LPL)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ beta3-adrenergic) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN beta3AR)) (-RRB- -RRB-))) (CC and) (NP (JJ hormone-sensitive) (NN lipase))) (PRN (-LRB- -LRB-) (NP (NN HSL)) (-RRB- -RRB-))) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (JJ brown) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (CC and) (NP (JJ epididymal) (-LRB- -LRB-) (NN EWAT) (-RRB- -RRB-) (CC and) (JJ perirenal) (-LRB- -LRB-) (NN PWAT) (-RRB- -RRB-) (JJ white) (NN adipose) (NN tissue)))) (PP (IN in) (NP (NP (CD three) (NNS groups)) (PP (IN of) (NP (NNS rats))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (NN food) (NN restriction)) (CC and) (NP (NN _PROT_) (NN administration))) (PP (IN on) (NP (NP (JJ several) (NNS transcripts)) (VP (VBN involved) (PP (IN in) (NP (NN energy) (NN homeostasis)))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (NP (NP (NP (NN _PROT1_)) (, ,) (NP (VBG _PROT2_) (NNS _PROT2_) (-LRB- -LRB-) (NN UCP) (-RRB- -RRB-) (CD 1) (, ,) (CD 2) (CC and) (CD 3)) (, ,) (NP (NP (NN lipoprotein) (NN lipase)) (PRN (-LRB- -LRB-) (NP (NN LPL)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ beta3-adrenergic) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN beta3AR)) (-RRB- -RRB-))) (CC and) (NP (JJ hormone-sensitive) (NN lipase))) (PRN (-LRB- -LRB-) (NP (NN HSL)) (-RRB- -RRB-))) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (JJ brown) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (CC and) (NP (JJ epididymal) (-LRB- -LRB-) (NN EWAT) (-RRB- -RRB-) (CC and) (JJ perirenal) (-LRB- -LRB-) (NN PWAT) (-RRB- -RRB-) (JJ white) (NN adipose) (NN tissue)))) (PP (IN in) (NP (NP (CD three) (NNS groups)) (PP (IN of) (NP (NNS rats))))))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VP (VBD increased) (NP (NP (NP (NN LPL) (NN mRNA)) (PP (IN by) (NP (CD 80) (NN %)))) (, ,) (NP (NN _PROT2_) (NN mRNA) (JJ twofold)) (, ,) (CC and) (NP (NN _PROT_) (NN mRNA) (NNS levels))) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN in) (NP (NN BAT)))))) (, ,) (CC and) (VP (VBD increased) (NP (NN _PROT_) (NN mRNA) (NNS levels)) (ADVP (RB twofold)) (PP (IN in) (NP (NN EWAT)))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VP (VBD increased) (NP (NP (NP (NN LPL) (NN mRNA)) (PP (IN by) (NP (CD 80) (NN %)))) (, ,) (NP (NN _PROT_) (NN mRNA) (JJ twofold)) (, ,) (CC and) (NP (NN _PROT2_) (NN mRNA) (NNS levels))) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN in) (NP (NN BAT)))))) (, ,) (CC and) (VP (VBD increased) (NP (NN _PROT_) (NN mRNA) (NNS levels)) (ADVP (RB twofold)) (PP (IN in) (NP (NN EWAT)))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VP (VBD increased) (NP (NP (NP (NN LPL) (NN mRNA)) (PP (IN by) (NP (CD 80) (NN %)))) (, ,) (NP (NN _PROT_) (NN mRNA) (JJ twofold)) (, ,) (CC and) (NP (NN _PROT_) (NN mRNA) (NNS levels))) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN in) (NP (NN BAT)))))) (, ,) (CC and) (VP (VBD increased) (NP (NN _PROT2_) (NN mRNA) (NNS levels)) (ADVP (RB twofold)) (PP (IN in) (NP (NN EWAT)))))))
-1 #(S1 (S (NP (NN _PROT_)) (VP (VP (VBD increased) (NP (NP (NP (NN LPL) (NN mRNA)) (PP (IN by) (NP (CD 80) (NN %)))) (, ,) (NP (NN _PROT1_) (NN mRNA) (JJ twofold)) (, ,) (CC and) (NP (NN _PROT2_) (NN mRNA) (NNS levels))) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN in) (NP (NN BAT)))))) (, ,) (CC and) (VP (VBD increased) (NP (NN _PROT_) (NN mRNA) (NNS levels)) (ADVP (RB twofold)) (PP (IN in) (NP (NN EWAT)))))))
-1 #(S1 (S (NP (NN _PROT_)) (VP (VP (VBD increased) (NP (NP (NP (NN LPL) (NN mRNA)) (PP (IN by) (NP (CD 80) (NN %)))) (, ,) (NP (NN _PROT1_) (NN mRNA) (JJ twofold)) (, ,) (CC and) (NP (NN _PROT_) (NN mRNA) (NNS levels))) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN in) (NP (NN BAT)))))) (, ,) (CC and) (VP (VBD increased) (NP (NN _PROT2_) (NN mRNA) (NNS levels)) (ADVP (RB twofold)) (PP (IN in) (NP (NN EWAT)))))))
-1 #(S1 (S (NP (NN _PROT_)) (VP (VP (VBD increased) (NP (NP (NP (NN LPL) (NN mRNA)) (PP (IN by) (NP (CD 80) (NN %)))) (, ,) (NP (NN _PROT_) (NN mRNA) (JJ twofold)) (, ,) (CC and) (NP (NN _PROT1_) (NN mRNA) (NNS levels))) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN in) (NP (NN BAT)))))) (, ,) (CC and) (VP (VBD increased) (NP (NN _PROT2_) (NN mRNA) (NNS levels)) (ADVP (RB twofold)) (PP (IN in) (NP (NN EWAT)))))))
+1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ increases) (NP (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN in) (NP (NN EWAT)))) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN LPL)))) (PP (IN in) (NP (NN BAT))))) (, ,) (SBAR (IN whereas) (S (NP (NP (VBN reduced) (NN food) (NN consumption)) (CONJP (CC but) (RB not)) (NP (NN leptin)) (, ,)) (VP (VBZ decreases) (NP (NN LPL) (NN expression)) (PP (IN in) (S (VP (VBD WAT)))))))))))))
+1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ increases) (NP (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN of) (NP (NN _PROT_))) (PP (IN in) (NP (NN EWAT)))) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN _PROT2_)) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN LPL)))) (PP (IN in) (NP (NN BAT))))) (, ,) (SBAR (IN whereas) (S (NP (NP (VBN reduced) (NN food) (NN consumption)) (CONJP (CC but) (RB not)) (NP (NN leptin)) (, ,)) (VP (VBZ decreases) (NP (NN LPL) (NN expression)) (PP (IN in) (S (VP (VBD WAT)))))))))))))
+1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ increases) (NP (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN of) (NP (NN _PROT_))) (PP (IN in) (NP (NN EWAT)))) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN LPL)))) (PP (IN in) (NP (NN BAT))))) (, ,) (SBAR (IN whereas) (S (NP (NP (VBN reduced) (NN food) (NN consumption)) (CONJP (CC but) (RB not)) (NP (NN leptin)) (, ,)) (VP (VBZ decreases) (NP (NN LPL) (NN expression)) (PP (IN in) (S (VP (VBD WAT)))))))))))))
-1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN _PROT_)) (VP (VBZ increases) (NP (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (NN EWAT)))) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN _PROT2_)) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN LPL)))) (PP (IN in) (NP (NN BAT))))) (, ,) (SBAR (IN whereas) (S (NP (NP (VBN reduced) (NN food) (NN consumption)) (CONJP (CC but) (RB not)) (NP (NN leptin)) (, ,)) (VP (VBZ decreases) (NP (NN LPL) (NN expression)) (PP (IN in) (S (VP (VBD WAT)))))))))))))
-1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN _PROT_)) (VP (VBZ increases) (NP (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (NN EWAT)))) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN LPL)))) (PP (IN in) (NP (NN BAT))))) (, ,) (SBAR (IN whereas) (S (NP (NP (VBN reduced) (NN food) (NN consumption)) (CONJP (CC but) (RB not)) (NP (NN leptin)) (, ,)) (VP (VBZ decreases) (NP (NN LPL) (NN expression)) (PP (IN in) (S (VP (VBD WAT)))))))))))))
-1 #(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN _PROT_)) (VP (VBZ increases) (NP (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN of) (NP (NN _PROT_))) (PP (IN in) (NP (NN EWAT)))) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN LPL)))) (PP (IN in) (NP (NN BAT))))) (, ,) (SBAR (IN whereas) (S (NP (NP (VBN reduced) (NN food) (NN consumption)) (CONJP (CC but) (RB not)) (NP (NN leptin)) (, ,)) (VP (VBZ decreases) (NP (NN LPL) (NN expression)) (PP (IN in) (S (VP (VBD WAT)))))))))))))
-1 #(S1 (S (S (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-))) (VP (VBZ is) (ADVP (RBR more)) (VP (VBN expressed) (PP (IN in) (DT the) (NN TEC/TNC) (IN than) (NP (NP (NN vasopressin)) (PRN (-LRB- -LRB-) (NP (NN VP)) (-RRB- -RRB-))))))) (: ;) (S (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN IGF-2)) (-RRB- -RRB-))) (JJ thymic) (NN expression)) (VP (VP (VBZ predominates) (PP (IN over) (NP (NN IGF-1)))) (, ,) (CC and) (VP (ADJP (RB much) (JJR more)) (PP (IN over) (NP (LST (-LRB- _PROT2_) (LS _PROT2_) (-RRB- _PROT2_)) (NN _PROT2_))))))))
-1 #(S1 (S (ADVP (RB Thus)) (, ,) (S (S (NP (NN _PROT1_)) (VP (VBD was) (VP (VBN proposed) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (NN self) (NN antigen)) (PP (IN of) (NP (DT the) (JJ neurohypophysial) (NN family)))))))))) (, ,) (CC and) (S (NP (NN IGF-2)) (NP (NP (DT the) (NN self) (NN antigen) (NN precursor)) (PP (IN of) (NP (DT the) (NN _PROT2_) (NN family))))))))
+1 #(S1 (S (NP (PRP We)) (VP (VBD observed) (SBAR (IN that) (S (NP (NP (JJ primary) (JJ microglial) (NNS cultures)) (CC and) (NP (DT the) (NN THP-1) (JJ monocytic) (NN cell) (NN line))) (VP (VBP are) (VP (VBN stimulated) (PP (IN by) (NP (JJ fibrillar) (NN beta-amyloid) (CC and) (NN _PROT1_) (NNS peptides))) (S (VP (TO to) (VP (VB activate) (NP (JJ identical) (NN _PROT2_) (JJ _PROT2_) (JJ inflammatory) (NN signal) (NN transduction) (NNS cascades))))))))))))
+1 #(S1 (S (NP (NP (NP (JJ Molecular) (NN characterization)) (PP (IN of) (NP (NP (NN catalytic-subunit) (NN cDNA) (NNS sequences)) (VP (VBG encoding) (NP (NN protein) (NNS phosphatases) (NP (NP (CD 1)) (CC and) (NP (NN 2A)))))))) (CC and) (NP (NP (NN study)) (PP (IN of) (NP (NP (PRP$ their) (NNS roles)) (PP (IN in) (NP (NP (DT the) (JJ _PROT1_) (NN _PROT2_) (NN expression)) (PP (IN in) (NP (NN rice)))))))))))
+1 #(S1 (S (S (VP (TO To) (VP (VB understand) (NP (NP (DT the) (JJ molecular) (NN mechanism)) (PP (IN of) (NP (JJ _PROT1_) (NN gene) (NN regulation))))))) (, ,) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (CD three) (NN phosphatase) (NNS inhibitors))) (PP (IN on) (NP (NP (NP (DT the) (NN germination)) (PP (IN of) (NP (NN rice) (NNS seeds)))) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT a) (NN target) (NN gene)) (, ,) (NP (DT the) (NN _PROT2_) (NN gene)) (, ,) (NP (NN Osamy-c)) (, ,))))))) (VP (VBD were) (VP (VBN measured))))))
+1 #(S1 (S (S (VP (TO To) (ADVP (RB further)) (VP (VB understand) (NP (NP (DT the) (JJ possible) (NN role)) (PP (IN of) (NP (NN protein) (NNS phosphatases) (NP (NP (CD 1)) (CC and) (NP (NN 2A))))) (PP (IN in) (NP (NP (DT the) (JJ _PROT1_) (NN expression)) (PP (IN of) (NP (NN _PROT2_))))))))) (, ,) (S (NP (PRP we)) (VP (VBD isolated) (NP (NP (NN cDNA) (NNS clones)) (VP (VBG encoding) (NP (NP (NN protein) (NN phosphatase) (CD 1)) (CC and) (NP (NN protein) (NN phosphatase) (NN 2A))))) (PP (IN from) (NP (DT a) (NN rice) (NN aleurone) (NN cDNA) (NN library)))))))
+1 #(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (PRP$ our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN protein) (NNS phosphatases) (NP (NP (NN PP1)) (CC or) (NP (NN PP2A)))) (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ _PROT1_) (NN expression)) (PP (IN of) (NP (DT the) (NN rice) (NN _PROT2_) (NN gene)))))) (, ,) (SBAR (IN though) (S (NP (NP (DT the) (NN PP1) (JJ or/and) (NN PP2A) (JJ enzymatic) (NNS activities)) (CONJP (RB as) (RB well) (IN as)) (NP (NN mRNA) (NNS levels))) (VP (VBP do) (RB not) (VP (VB increase) (PP (IN upon) (NP (NN GA3) (NN treatment))))))))))))))
+1 #(S1 (S (NP (NP (NN _PROT1_) (NN treatment)) (PP (IN of) (NP (JJ fetal) (NN guinea) (NN pig) (NN brain) (NNS cultures)))) (ADVP (RB substantially)) (VP (VP (VBD reduced) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))))) (PP (IN in) (NP (DT the) (NN medium)))) (CC but) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN sAPPalpha)))))))
+1 #(S1 (S (NP (NP (NN _PROT1_) (NN treatment)) (PP (IN of) (NP (JJ fetal) (NN guinea) (NN pig) (NN brain) (NNS cultures)))) (ADVP (RB substantially)) (VP (VP (VBD reduced) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))))) (PP (IN in) (NP (DT the) (NN medium)))) (CC but) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN sAPPalpha)))))))
-1 #(S1 (S (NP (NP (NN _PROT_) (NN treatment)) (PP (IN of) (NP (JJ fetal) (NN guinea) (NN pig) (NN brain) (NNS cultures)))) (ADVP (RB substantially)) (VP (VP (VBD reduced) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))))) (PP (IN in) (NP (DT the) (NN medium)))) (CC but) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN sAPPalpha)))))))
+1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (JJ parental) (NN line)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NN _PROT1_))))))) (, ,) (S (S (NP (NP (NN _PROT2_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN sAPPbeta))) (VP (VBD decreased) (PP (TO to) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ mutant) (NN line))))))))))) (, ,) (CC and) (S (NP (DT the) (JJ mutant) (NN line)) (VP (VBD was) (ADJP (JJ resistant) (PP (TO to) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN _PROT_)))))))))))
+1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (JJ parental) (NN line)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NN _PROT1_))))))) (, ,) (S (S (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN sAPPbeta))) (VP (VBD decreased) (PP (TO to) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ mutant) (NN line))))))))))) (, ,) (CC and) (S (NP (DT the) (JJ mutant) (NN line)) (VP (VBD was) (ADJP (JJ resistant) (PP (TO to) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN _PROT_)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (JJ parental) (NN line)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NN _PROT1_))))))) (, ,) (S (S (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN sAPPbeta))) (VP (VBD decreased) (PP (TO to) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ mutant) (NN line))))))))))) (, ,) (CC and) (S (NP (DT the) (JJ mutant) (NN line)) (VP (VBD was) (ADJP (JJ resistant) (PP (TO to) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN _PROT2_)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (JJ parental) (NN line)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NN _PROT_))))))) (, ,) (S (S (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN sAPPbeta))) (VP (VBD decreased) (PP (TO to) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ mutant) (NN line))))))))))) (, ,) (CC and) (S (NP (DT the) (JJ mutant) (NN line)) (VP (VBD was) (ADJP (JJ resistant) (PP (TO to) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN _PROT_)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (JJ parental) (NN line)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NN _PROT_))))))) (, ,) (S (S (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN sAPPbeta))) (VP (VBD decreased) (PP (TO to) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ mutant) (NN line))))))))))) (, ,) (CC and) (S (NP (DT the) (JJ mutant) (NN line)) (VP (VBD was) (ADJP (JJ resistant) (PP (TO to) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN _PROT2_)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (JJ parental) (NN line)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NN _PROT_))))))) (, ,) (S (S (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT1_)) (, ,) (CC and) (NP (NN sAPPbeta))) (VP (VBD decreased) (PP (TO to) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ mutant) (NN line))))))))))) (, ,) (CC and) (S (NP (DT the) (JJ mutant) (NN line)) (VP (VBD was) (ADJP (JJ resistant) (PP (TO to) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN _PROT2_)))))))))))
+1 #(S1 (S (S (NP (NN _PROT1_)) (VP (VBZ stimulates) (NP (NN tyrosine) (NN phosphorylation)) (PP (IN by) (NP (NP (NN activation)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN in) (NP (DT the) (NN rat) (JJ smooth) (NN muscle) (NN cell) (NN line))))))) (, ,) (NP (NN A-10))))
+1 #(S1 (S (NP (NP (DT The) (NP (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NNS inhibitors)) (: :) (NP (NP (NN staurosporine)) (, ,) (NP (NN H7)) (CC and) (NP (NN GF109203X)))) (VP (VBP are) (ADJP (JJ able) (S (VP (TO to) (VP (VB block) (NP (DT the) (JJ _PROT2_) (NN phosphorylation)))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ is) (ADVP (RB upstream) (PP (IN of) (NP (DT the) (NN phosphorylation)))) (, ,) (NP (NP (DT a) (NN motion)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN supported) (PP (IN by) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (DT the) (JJ _PROT2_) (NN phosphorylation)) (VP (VBD was) (VP (VBN downregulated) (PP (IN by) (NP (NN phorbol) (NNS esters))))))))))))))))))))
+1 #(S1 (S (NP (JJ Aggregated) (NN beta) (NN _PROT1_) (NN peptide) (NN 1-40)) (VP (VBZ decreases) (NP (NP (NN Ca2+-)) (CC and) (NP (JJ cholinergic) (JJ receptor-mediated) (NN phosphoinositide) (NN degradation))) (PP (IN by) (NP (NP (NN alteration)) (PP (IN of) (NP (NP (NN membrane)) (CC and) (NP (JJ cytosolic) (NN _PROT2_) (NN _PROT2_)))) (PP (IN in) (NP (NN brain) (NN cortex))))))))
-1 #(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ full-length) (NN _PROT1_) (NN beta) (NN protein)) (, ,) (NP (NP (NP (NN A)) (PRN (-LRB- -LRB-) (NP (NN beta)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN 1-40)) (-RRB- -RRB-))) (, ,))) (PP (IN on) (NP (NP (JJ phosphoinositide-specific) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PLC)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN investigated) (PP (IN in) (NP (NP (NP (JJ synaptic) (NN plasma) (NNS membranes)) (PRN (-LRB- -LRB-) (NP (NN SPM)) (-RRB- -RRB-))) (CC and) (NP (NP (NN cytosol)) (VP (VBN prepared) (PP (IN from) (NP (NP (DT the) (JJ cerebral) (NN cortex)) (PP (IN of) (NP (JJ adult) (NNS rats)))))))))))))
-1 #(S1 (S (S (NP (NP (JJ Aggregated) (NN _PROT1_)) (PRN (-LRB- _PROT1_) (NP (NN _PROT1_)) (-RRB- _PROT1_))) (ADVP (RB also)) (VP (VBD decreased) (ADVP (RB significantly)) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN diacylglycerol)))))) (, ,) (NP (NP (DT the) (NN product)) (PP (IN of) (NP (NN _PROT2_))))))
+1 #(S1 (S (NP (DT This)) (ADVP (RB additionally)) (VP (VBZ supports) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NP (NN _PROT1_)) (PRN (-LRB- _PROT1_) (NP (NN _PROT1_)) (-RRB- _PROT1_)))) (PP (IN on) (NP (ADJP (ADJP (JJ membrane-bound)) (CC and) (ADJP (JJ cytosolic))) (NN _PROT2_)))))))
+1 #(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NP (NN _PROT1_)) (PRN (-LRB- _PROT1_) (NP (NN _PROT1_)) (-RRB- _PROT1_))) (PRN (-LRB- _PROT1_) (NP (NN _PROT1_)) (-RRB- _PROT1_))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (DT the) (JJ basal) (NN activity)) (PP (IN of) (NP (DT the) (NN _PROT2_))) (PP (IN in) (NP (NN SPM)))) (CC and) (NP (NP (DT the) (NN enzyme) (NN activity)) (VP (VBN regulated) (PP (IN through) (NP (JJ cholinergic) (NNS receptors)))))))))
-1 #(S1 (S (NP (CD Ten) (NN _PROT1_) (NNS _PROT1_)) (VP (VBP have) (VP (VBN been) (VP (VBN assayed) (PP (IN for) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB phosphorylate) (ADVP (FW in) (FW vitro)) (NP (NP (NP (DT the) (JJ _PROT2_) (JJ _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN 25-242)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN rbPrP)) (-RRB- -RRB-)))))))))))))
+1 #(S1 (S (PP (IN With) (NN regard) (TO to) (NP (NN _PROT1_))) (, ,) (NP (NN phosphorylation)) (VP (VBZ occurs) (PP (IN at) (NP (NN Ser) (CD 154))) (PP (IN with) (NP (NP (DT a) (NN stoichiometry)) (PP (IN of) (NP (QP (RB about) (CD 0.1)) (NN mol) (NN phosphate/mol) (NN _PROT2_))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN doubled) (PP (IN by) (NP (NP (JJ mild) (NN heat) (NN treatment)) (PP (IN of) (NP (NN _PROT_))))))))))))))
-1 #(S1 (S (PP (IN With) (NN regard) (TO to) (NP (NN _PROT1_))) (, ,) (NP (NN phosphorylation)) (VP (VBZ occurs) (PP (IN at) (NP (NN Ser) (CD 154))) (PP (IN with) (NP (NP (DT a) (NN stoichiometry)) (PP (IN of) (NP (QP (RB about) (CD 0.1)) (NN mol) (NN phosphate/mol) (NN _PROT_))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN doubled) (PP (IN by) (NP (NP (JJ mild) (NN heat) (NN treatment)) (PP (IN of) (NP (NN _PROT2_))))))))))))))
-1 #(S1 (S (PP (IN With) (NN regard) (TO to) (NP (NN _PROT_))) (, ,) (NP (NN phosphorylation)) (VP (VBZ occurs) (PP (IN at) (NP (NN Ser) (CD 154))) (PP (IN with) (NP (NP (DT a) (NN stoichiometry)) (PP (IN of) (NP (QP (RB about) (CD 0.1)) (NN mol) (NN phosphate/mol) (NN _PROT1_))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN doubled) (PP (IN by) (NP (NP (JJ mild) (NN heat) (NN treatment)) (PP (IN of) (NP (NN _PROT2_))))))))))))))
+1 #(S1 (S (IN In) (S (NP (NP (DT the) (JJ fasting) (NN state)) (NN _PROT1_) (NN expression)) (VP (VBD correlated) (ADVP (RB inversely)) (PP (IN with) (NP (NP (NP (NN body) (NN mass) (NN index)) (PRN (-LRB- -LRB-) (NP (NP (NN r)) (VP (VBG =) (NP (CD -0.45)))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.026)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ percent) (NN body) (NN fat)) (PRN (-LRB- -LRB-) (NP (NP (NN r)) (VP (VBG =) (NP (CD -0.41)))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.05)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN plasma) (NN insulin)) (PRN (-LRB- -LRB-) (NP (NP (NN r)) (VP (VBG =) (NP (CD -0.47)))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.02)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ epigastric) (JJ venous) (JJ fatty) (NNS acids)) (PRN (-LRB- -LRB-) (NP (NP (NN r)) (VP (VBG =) (NP (CD -0.45)))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.04)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN _PROT2_)))) (PRN (-LRB- -LRB-) (NP (NP (NN r)) (VP (VBG =) (NP (CD -0.50)))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.018)))) (-RRB- -RRB-))))))
+1 #(S1 (S (NP (NN _PROT1_) (NN expression)) (VP (VBD remained) (ADJP (RB inversely) (JJ related) (PP (IN with) (NP (NN plasma) (NN _PROT2_)))) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (JJ percent) (NN body)))))) (PRN (-LRB- -LRB-) (NP (NP (NN r)) (ADJP (JJ =) (NP (CD -0.45)))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.038)))) (-RRB- -RRB-)))))
+1 #(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (LST (LS 1) (-RRB- -RRB-)) (NP (NP (NN _PROT1_) (NN messenger) (NN ribonucleic) (NN acid) (NN expression)) (PP (IN in) (NP (JJ sc) (NN adipose) (NN tissue)))) (VP (VP (VBZ is) (ADJP (RB inversely) (JJ related) (PP (TO to) (NP (NN adiposity))))) (CC and) (VP (ADVP (RB independently)) (VBN linked) (PP (TO to) (NP (JJ local) (NN plasma) (NN _PROT2_) (NNS levels)))))) (: ;) (CC and) (LST (LS 2) (-RRB- -RRB-)) (S (NP (NN _PROT_) (NN expression)) (VP (VBZ is) (RB not) (ADVP (RB acutely)) (VP (VBN regulated) (PP (IN by) (NP (NP (NN food) (NN intake)) (, ,) (NP (NN insulin)) (, ,) (CC or) (NP (JJ fatty) (NNS acids)))))))))
-1 #(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (LST (LS 1) (-RRB- -RRB-)) (NP (NP (NN _PROT1_) (NN messenger) (NN ribonucleic) (NN acid) (NN expression)) (PP (IN in) (NP (JJ sc) (NN adipose) (NN tissue)))) (VP (VP (VBZ is) (ADJP (RB inversely) (JJ related) (PP (TO to) (NP (NN adiposity))))) (CC and) (VP (ADVP (RB independently)) (VBN linked) (PP (TO to) (NP (JJ local) (NN plasma) (NN _PROT_) (NNS levels)))))) (: ;) (CC and) (LST (LS 2) (-RRB- -RRB-)) (S (NP (NN _PROT2_) (NN expression)) (VP (VBZ is) (RB not) (ADVP (RB acutely)) (VP (VBN regulated) (PP (IN by) (NP (NP (NN food) (NN intake)) (, ,) (NP (NN insulin)) (, ,) (CC or) (NP (JJ fatty) (NNS acids)))))))))
-1 #(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (LST (LS 1) (-RRB- -RRB-)) (NP (NP (NN _PROT_) (NN messenger) (NN ribonucleic) (NN acid) (NN expression)) (PP (IN in) (NP (JJ sc) (NN adipose) (NN tissue)))) (VP (VP (VBZ is) (ADJP (RB inversely) (JJ related) (PP (TO to) (NP (NN adiposity))))) (CC and) (VP (ADVP (RB independently)) (VBN linked) (PP (TO to) (NP (JJ local) (NN plasma) (NN _PROT1_) (NNS levels)))))) (: ;) (CC and) (LST (LS 2) (-RRB- -RRB-)) (S (NP (NN _PROT2_) (NN expression)) (VP (VBZ is) (RB not) (ADVP (RB acutely)) (VP (VBN regulated) (PP (IN by) (NP (NP (NN food) (NN intake)) (, ,) (NP (NN insulin)) (, ,) (CC or) (NP (JJ fatty) (NNS acids)))))))))
-1 #(S1 (S (NP (NP (NN Influence)) (PP (IN of) (NP (NP (NN obesity)) (CC and) (NP (JJ menopausal) (NN status)))) (PP (IN on) (NP (NP (NP (NN serum) (NN _PROT1_)) (, ,) (NP (NN cholecystokinin)) (, ,) (NP (NN galanin)) (CC and) (NP (NN _PROT2_) (NN _PROT2_))) (NNS levels))))))
-1 #(S1 (S (NP (NN Obesity)) (VP (VP (VBZ occurs) (PP (IN in) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (NP (NNS women)) (PP (IN after) (NP (NN menopause)))))))) (CC and) (VP (VBZ is) (VP (VBN characterized) (PP (IN by) (NP (NP (DT an) (NN excess)) (PP (IN of) (NP (NN adipose) (NN tissue)))))))) (SBAR (WHNP (WDT that)) (S (VP (VBZ depends) (PP (IN on) (NP (JJ several) (ADJP (ADJP (ADJP (JJ orexigenic)) (PRN (-LRB- -LRB-) (S (S (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (VP (VBZ stimulates) (NP (NN carbohydrate) (NN ingestion)))) (, ,) (S (NP (NN galanin)) (VP (VBZ stimulates) (NP (JJ fat) (NN intake))))) (-RRB- -RRB-))) (CC and) (ADJP (ADJP (JJ anorectic)) (PRN (-LRB- -LRB-) (NP (NP (NN _PROT2_)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-)))) (-RRB- -RRB-)))) (NNS factors))))))))
+1 #(S1 (S (NP (CC Both) (NP (NN _PROT1_)) (CC and) (NP (NN insulin))) (VP (MD can) (VP (VB reduce) (NP (NP (JJ hypothalamic) (NN _PROT2_) (NN production)) (CC and) (NP (NN secretion)))))))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (JJ basal) (NNS levels)) (PP (IN of) (NP (NP (NP (NN serum) (NN _PROT1_)) (, ,) (NP (NN CCK)) (, ,) (NP (NN galanin)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (CD 16) (JJ non-obese) (JJ premenopausal) (NNS women))) (, ,) (PP (IN in) (NP (NP (CD 15) (JJ obese) (JJ premenopausal) (NNS women)) (PRN (-LRB- -LRB-) (NP (NN body) (NN mass) (NN index) (-LRB- -LRB-) (NN BMI) (-RRB- -RRB-) (QP (CD 34.6) (CC +/-) (CD 1.3)) (NN SD)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (CD ten) (JJ obese) (JJ postmenopausal) (NNS women)) (PRN (-LRB- -LRB-) (NP (NN BMI) (CD 34.7) (CC +/-) (CD 1.5) (NN SD)) (-RRB- -RRB-)))))))))) (S (VP (TO to) (VP (VB determine) (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN obesity)) (, ,) (NP (NN menopause)) (CC and) (NP (DT these) (NNS neuropeptides)))))))))
-1 #(S1 (S (NP (NP (ADJP (RB Significantly) (VBN increased)) (NP (NP (NN _PROT1_)) (CC and) (NP (NN galanin))) (NNS levels)) (PP (IN in) (NP (NP (JJ postmenopausal) (JJ obese) (NNS women)) (VP (VBN coupled) (PP (IN with) (NP (VBN decreased) (NN _PROT2_) (NNS levels))))))) (VP (VBD revealed) (NP (NP (DT some) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS neuropeptides)) (VP (VBG regulating) (NP (JJ eating) (NN behavior))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (NP (NP (DT the) (NN reason)) (PP (IN for) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (JJ postmenopausal) (NN obesity))))))))))))))
+1 #(S1 (S (NP (DT A) (NN loop) (NN system)) (VP (VBZ exists) (PP (IN between) (NP (NP (NP (JJ hypothalamic) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (CC and) (NP (JJ peripheral) (NN adipose) (NN tissue) (NN _PROT2_)))) (S (VP (TO to) (VP (VB maintain) (NP (JJ normal) (NN body) (NN homeostasis))))))))
+1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN infused) (NP (NN i.c.v.)) (PP (TO to) (NP (JJ normal) (NNS rats))) (S (VP (TO to) (VP (VB mimic) (NP (PRP$ its) (JJ central) (NNS effects)))))))) (, ,) (S (NP (NN _PROT1_)) (VP (VBZ decreases) (NP (NP (NN _PROT2_) (NNS levels)) (, ,) (ADVP (RB thus)) (NP (NP (NN food) (NN intake)) (CC and) (NP (NN body) (NN weight))))))))
-1 #(S1 (S (NP (NP (JJ Circadian) (NNS fluctuations)) (PP (IN of) (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (NNS levels)))) (VP (VBP maintain) (NP (JJ normal) (NN body) (NN homeostasis)))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VP (VBZ increases) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN _PROT2_) (NNS _PROT2_)))) (PRN (-LRB- -LRB-) (NP (NP (NN UCP-1)) (, ,) (NP (CD -2)) (, ,) (NP (CD -3))) (-RRB- -RRB-))) (CC and) (VP (ADVP (RB thus)) (NP (NN energy) (NN dissipation))))))
+1 #(S1 (S (PP (VBN Compared) (PP (IN with) (NP (DT the) (JJ wild) (NN type)))) (, ,) (NP (NP (NN _PROT1_) (NN induction)) (PP (IN of) (NP (JJ _PROT2_) (NN activity))) (PP (IN in) (NP (NP (NN aleurone) (NNS cells)) (PP (IN of) (NP (NN d1)))))) (VP (VBD was) (ADVP (RB greatly)) (VP (VBN reduced)))))
+1 #(S1 (S (PP (JJ Relative) (TO to) (NP (DT the) (JJ wild) (NN type))) (, ,) (NP (NP (DT the) (NN _PROT1_) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-) (JJ -treated) (NN aleurone) (NN layer)) (PP (IN of) (NP (NN d1)))) (VP (VBD had) (NP (NP (JJR lower) (NN expression)) (PP (IN of) (NP (NN Ramy1A))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (NP (NP (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN OsGAMYB))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (DT a) (JJ _PROT_) (JJ transcriptional) (NN factor))))) (, ,)) (CC and) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (NN Ca)) (PRN (-LRB- -LRB-) (NP (CD 2)) (CC +) (-RRB- -RRB-))) (NN -ATPase))))))))))))))
-1 #(S1 (S (PP (JJ Relative) (TO to) (NP (DT the) (JJ wild) (NN type))) (, ,) (NP (NP (DT the) (NN _PROT1_) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-) (JJ -treated) (NN aleurone) (NN layer)) (PP (IN of) (NP (NN d1)))) (VP (VBD had) (NP (NP (JJR lower) (NN expression)) (PP (IN of) (NP (NN Ramy1A))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (NP (NP (NP (NN _PROT_)) (, ,) (CC and) (NP (NN OsGAMYB))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (DT a) (JJ _PROT2_) (JJ transcriptional) (NN factor))))) (, ,)) (CC and) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (NN Ca)) (PRN (-LRB- -LRB-) (NP (CD 2)) (CC +) (-RRB- -RRB-))) (NN -ATPase))))))))))))))
-1 #(S1 (S (PP (JJ Relative) (TO to) (NP (DT the) (JJ wild) (NN type))) (, ,) (NP (NP (DT the) (NN _PROT_) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-) (JJ -treated) (NN aleurone) (NN layer)) (PP (IN of) (NP (NN d1)))) (VP (VBD had) (NP (NP (JJR lower) (NN expression)) (PP (IN of) (NP (NN Ramy1A))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (NP (NP (NP (NN _PROT1_)) (, ,) (CC and) (NP (NN OsGAMYB))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (DT a) (JJ _PROT2_) (JJ transcriptional) (NN factor))))) (, ,)) (CC and) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (NN Ca)) (PRN (-LRB- -LRB-) (NP (CD 2)) (CC +) (-RRB- -RRB-))) (NN -ATPase))))))))))))))
+1 #(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (DT the) (NN presence) (IN of) (NP (JJ high) (NN _PROT1_) (NNS concentrations))) (, ,) (NP (NN _PROT2_) (NN induction)) (VP (VBD occurred) (ADVP (RB even)) (PP (IN in) (NP (NN d1))))))
+1 #(S1 (S (NP (PDT All) (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN d1)) (VP (VBZ affects) (NP (NP (NP (DT a) (NN part)) (PP (IN of) (NP (DT the) (JJ _PROT1_) (NN pathway)))) (, ,) (NP (NP (RB namely) (DT the) (NN induction)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN in) (NP (DT the) (NN aleurone) (NN layer)))) (CC and) (NP (NN internode) (NN elongation)))))))))
+1 #(S1 (S (NP (NN Arcuate) (NN nucleus) (NN _PROT1_) (NN mRNA)) (VP (VBD increased) (PP (IN in) (NP (NP (NNS rats)) (PP (IN given) (NP (JJ protein-free) (NN diet))))) (, ,) (S (VP (VBG correlating) (PP (IN with) (NP (NP (NN _PROT2_)) (CONJP (RB rather) (IN than)) (NP (VBN decreased) (NN feeding)))))))))
